We believe that the opportunity for CNS repair relies on our ability to manufacture autologous (patient-specific) neuronal precursor cells with a high level of potency and consistency at a scale and efficiency that can meet development and, eventually, commercial demand. Fortuna Fix's manufacturing process of the drNPC™ family of cells under development is a fully automated process that will allow for large scale production of therapeutic regenerative medicine cell products. Quality is critical to the successful development of our therapies. We are therefore focusing on integrating a scalable and efficient cell manufacturing process, along with testing, storage and distribution.